October 24, 2016
FDA gives green light to Merck’s CDI drug
The US FDA has approved Merck’s Zinplava (bezlotoxumab) Injection 25 mg/mL, which …
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Merck
October 21, 2016
Merck’s Keytruda shows success in key bladder cancer trial
Merck announced that the phase 3 keynote-045 trial investigating the use of Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS).
October 12, 2016
Ablynx, Merck further extend their collaboration on ion channel research, Ablynx gets €1M
Ablynx has extended for a second time its research collaboration with a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada, to develop and commercialise Nanobody candidates directed towards an undisclosed voltage gated ion channel.
October 9, 2016
New Data on the Combination of Lilly’s ALIMTA and Merck’s KEYTRUDA
Important clinical study results from one of Eli Lilly and Company’s ongoing immuno-oncology collaborations with Merck (known as MSD outside…
March 10, 2016
Sanofi and MSD/Merck in joint vaccines operations in Europe
Sanofi and MSD/Merck in joint vaccines operations in Europe
November 19, 2015
Lilly and Merck move on with oncology clinical trial of and Keytruda
Eli Lilly and Merck are moving on with an existing oncology clinical trial collaboration to evaluate the safety and efficacy of the combination of Lilly’s Almita (pemetrexed for injection) and Merck’s Keytruda (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC).
October 8, 2015
Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
Merck KGaA and Pfizer have announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.
October 6, 2015
Merck: Results of Phase 3 Study of Investigational Chronic Hepatitis C Therapy
Merck has announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection.